Dr. Jamal Misleh, MD
Claim this profileMedical Oncology Hematology Consultants, PA
About Jamal Misleh, MD
Education:
- Obtained MD from the University of Miami School of Medicine in 2003.
Experience:
- Completed an Internal Medicine Internship (2003-2004) and Residency (2004-2006) at the Hospital of the University of Pennsylvania.
- Undertook a Fellowship in Hematology/Medical Oncology at the University of Maryland Medical Center (2006-2009).
- Board Certified in Hematology and Medical Oncology by the American Board of Internal Medicine since 2009.
- Affiliated with Medical Oncology Hematology Consultants, PA, and serves as the Director of US Oncology Network Clinical Trials.
Area of expertise
Breast Cancer
Jamal Misleh, MD has run 11 trials for Breast Cancer. Some of their research focus areas include:
Pancreatic Cancer
Jamal Misleh, MD has run 7 trials for Pancreatic Cancer. Some of their research focus areas include:
Affiliated Hospitals
Christiana Care Health Services
Medical Oncology Hematology Consultants PA
Clinical Trials Jamal Misleh, MD is currently running
Genomic Testing
for Breast Cancer
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Recruiting
1 award
N/A
3 criteria
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting
1 award
Phase 2
5 criteria
More about Jamal Misleh, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Jamal Misleh, MD has experience with
- Pembrolizumab
- Abemaciclib
- Placebo
- LOXO-305
- Rituximab
- Botensilimab
Breakdown of trials Jamal Misleh, MD has run
Breast Cancer
Pancreatic Cancer
Lung Cancer
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jamal Misleh, MD specialize in?
Jamal Misleh, MD focuses on Breast Cancer and Pancreatic Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jamal Misleh, MD currently recruiting for clinical trials?
Yes, Jamal Misleh, MD is currently recruiting for 5 clinical trials in Newark Delaware. If you're interested in participating, you should apply.
Are there any treatments that Jamal Misleh, MD has studied deeply?
Yes, Jamal Misleh, MD has studied treatments such as Pembrolizumab, Abemaciclib, Placebo.
What is the best way to schedule an appointment with Jamal Misleh, MD?
Apply for one of the trials that Jamal Misleh, MD is conducting.
What is the office address of Jamal Misleh, MD?
The office of Jamal Misleh, MD is located at: Medical Oncology Hematology Consultants, PA, Newark, Delaware 19713 United States. This is the address for their practice at the Medical Oncology Hematology Consultants, PA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.